The impact of Covid-19 on the Indian pharmaceutical companies was relatively limited in FY2021 owing to the inelastic demand for pharmaceutical ...
Read more: Minimal impact of Covid 2.0 on the Indian pharma industry; ICRA estimates FY22 growth at 7-9%